Previous Section
Clinical Trials
11. Lamivudine is not effective in primary Sjogren's syndrome.
- Author
- Gescuk B; Wu AJ; Whitcher JP; Daniels TE; Lund S; Fye K; Davis JC Jr;
- Institution
- Clinical Trials Center, Division of Rheumatology, University of California, San Francisco, 533 Parnassus Avenue Box 0633 Room U383, San Francisco, CA 94143-0633, USA.
- Journal
- Ann Rheum Dis. 2005 Sep;64(9):1326-30. Epub 2005 Feb 11.
- Abstract URL
- Click here to view abstract
12. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca.
- Author
- Stonecipher K; Perry HD; Gross RH; Kerney DL;
- Institution
- Southeastern Laser and Refractive Center, Greensboro, NC, USA.
- Journal
- Curr Med Res Opin. 2005 Jul;21(7):1057-63.
- Abstract URL
- Click here to view abstract
13. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
- Author
- Barber LD; Pflugfelder SC; Tauber J; Foulks GN;
- Institution
- Department of Ophthalmology, University of Arkansas, Little Rock, Arkansas 72205, USA.
- Journal
- Ophthalmology. 2005 Oct;112(10):1790-4.
- Abstract URL
- Click here to view abstract
14. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study.
- Author
- Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H;
- Institution
- Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, The Netherlands. j.pijpe@kchir.umcg.nl
- Journal
- Arthritis Rheum. 2005 Sep;52(9):2740-50.
- Abstract URL
- Click here to view abstract
15. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome.
- Author
- Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X;
- Institution
- Department of Rheumatology, Hopital Bicetre, Assistance Publique-Hopitaux de Paris, Universite paris-Sud 11, INSERM U802, Le Kremlin Bicetre, France.
- Journal
- Ann Rheum Dis. 2007 Mar;66(3):351-7. Epub 2006 Sep 1.
- Abstract URL
- Click here to view abstract
16. Systemic sclerosis-associated Sjogren's syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients.
- Author
- Avouac J; Sordet C; Depinay C; Ardizonne M; Vacher-Lavenu MC; Sibilia J; Kahan A; Allanore Y; Avouac J; Sordet C; Depinay C; Ardizonne M; Vacher-Lavenu MC; Sibilia J; Kahan A; Allanore Y; Avouac J; Sordet C; Depinay C; Ardizonne M; Vacher-Lavenu MC; Sibilia J; Kahan A; Allanore Y; Avouac J; Sordet C; Depinay C; Ardizonne M; Vacher-Lavenu MC; Sibilia J; Kahan A; Allanore Y;
- Institution
- Rene Descartes University, Medical Faculty, Hopital Cochin, France.
- Journal
- Arthritis Rheum. 2006 Jul;54(7):2243-9.
- Abstract URL
- Click here to view abstract
17. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study.
- Author
- Steinfeld SD; Tant L; Burmester GR; Teoh NK; Wegener WA; Goldenberg DM; Pradier O;
- Institution
- Department of Rheumatology, Erasme University Hospital, 808 Route de Lennik, Brussels 1070, Belgium. ssteinfe@ulb.ac.be
- Journal
- Arthritis Res Ther. 2006;8(4):R129.
- Abstract URL
- Click here to view abstract
